⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis

John Mascarenhas Anna Ritá Migliaccio Heidi Kosiorek Rupali Bhave Jeanne Palmer Andrew Kuykendall Ruben A. Mesa Raajit K. Rampal Aaron T. Gerds Abdulraheem Yacoub Kristen Pettit Moshe Talpaz Rami S. Komrokji Marina Kremyanskaya Agapito Gonzalez Frank Fabris Kathryn Johnson Mikaela Dougherty Erin McGovern Juan Arango Ossa Dylan Domenico Noushin Farnoud Rona Singer Weinberg Amy Kong Vesna Najfeld Alessandro M. Vannucchi Francesca Arciprete Maria Zingariello Mario Falchi Mohamed E. Salama Carolyn Mead‐Harvey Amylou C. Dueck Lilian Varricchio Ronald Hoffman

View at Publisher

Ask AI

Bookmark

Share

Abstract

PK data for Cycle 1 (first 24 hours only) for A) 180 mg/m2 dose level and B) 550 mg/m2 dose level during dose escalation phase I.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mascarenhas et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875238e5 https://doi.org/10.1158/1078-0432.27033157.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S9 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis2024
2Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis2024
3Supplementary Figure S4 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis2024
4Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis2024
5Supplementary Figure S3 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis2024

More related papers

Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis2024
Supplementary Figure S7 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis2024
Supplementary Figure S8 from A Phase 1b trial of AVID200, a TGFβ 1/3 trap, in patients with myelofibrosis2024